2021
Effects of Atrial Fibrillation on Heart Failure Outcomes and NT-proBNP Levels in the GUIDE-IT Trial
Chouairi F, Pacor J, Miller PE, Fuery MA, Caraballo C, Sen S, Leifer ES, Felker GM, Fiuzat M, O’Connor C, Januzzi JL, Friedman DJ, Desai NR, Ahmad T, Freeman JV. Effects of Atrial Fibrillation on Heart Failure Outcomes and NT-proBNP Levels in the GUIDE-IT Trial. Mayo Clinic Proceedings Innovations Quality & Outcomes 2021, 5: 447-455. PMID: 33997640, PMCID: PMC8105522, DOI: 10.1016/j.mayocpiqo.2021.02.005.Peer-Reviewed Original ResearchNT-proBNP levelsReduced ejection fractionAtrial fibrillationHF hospitalizationHeart failureEjection fractionMedical therapyN-terminal pro-B-type natriuretic peptideOptimal guideline-directed medical therapyPro-B-type natriuretic peptideGuideline-directed medical therapyHigher NT-proBNP concentrationsHigher NT-proBNP levelsGUIDE-IT trialMedical therapy useHeart failure outcomesHeart Failure TrialPrevalent atrial fibrillationNT-proBNP concentrationsType natriuretic peptideEvidence-based therapiesCardiovascular deathAF patientsTherapy useFailure Trial
2019
Outcomes and Anticoagulation Use After Catheter Ablation for Atrial Fibrillation
Freeman JV, Shrader P, Pieper KS, Allen LA, Chan PS, Fonarow GC, Gersh BJ, Kowey PR, Mahaffey KW, Naccarelli G, Reiffel JA, Singer DE, Go AS, Hylek EM, Steinberg BA, Peterson ED, Piccini JP. Outcomes and Anticoagulation Use After Catheter Ablation for Atrial Fibrillation. Circulation Arrhythmia And Electrophysiology 2019, 12: e007612. PMID: 31830822, DOI: 10.1161/circep.119.007612.Peer-Reviewed Original ResearchConceptsAF catheter ablationOral anticoagulationRisk of strokeAF ablationCatheter ablationAntiarrhythmic medicationsDe novo AF ablationDiscontinuation of OACPropensity score-matched cohortAtrial fibrillation catheter ablationAF ablation patientsAnti-arrhythmic medicationsAtrial Fibrillation RegistryStroke prevention therapyBetter Informed TreatmentCohort of patientsPatterns of treatmentProportional hazards regressionUS national registryAnticoagulation useCause deathMajor bleedingSystemic embolismCardiovascular deathCause hospitalization
2018
Pharmacotherapy for Atrial Fibrillation in Patients With Chronic Kidney Disease: Insights From ORBIT‐AF
Washam JB, Holmes DN, Thomas LE, Pokorney SD, Hylek EM, Fonarow GC, Mahaffey KW, Gersh BJ, Kowey PR, Ansell JE, Go AS, Reiffel JA, Freeman JV, Singer DE, Naccarelli G, Blanco R, Peterson ED, Piccini JP. Pharmacotherapy for Atrial Fibrillation in Patients With Chronic Kidney Disease: Insights From ORBIT‐AF. Journal Of The American Heart Association 2018, 7: e008928. PMID: 30371218, PMCID: PMC6222961, DOI: 10.1161/jaha.118.008928.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAgedAged, 80 and overAnti-Arrhythmia AgentsAnticoagulantsAtrial FibrillationDabigatranDrug Therapy, CombinationFemaleFollow-Up StudiesHumansMaleMiddle AgedProspective StudiesRegistriesRenal Insufficiency, ChronicRisk FactorsStrokeTime FactorsTreatment OutcomeWarfarinConceptsBackground Chronic kidney diseaseAntiarrhythmic drug useTransient ischemic attackChronic kidney diseaseAtrial fibrillationAdvanced CKDCKD statusIschemic attackSystemic embolismCause mortalityCreatinine clearanceRhythm controlKidney diseaseDrug useAtrial fibrillation scoreBaseline renal functionOral anticoagulant useRhythm control strategyCox proportional hazardsCKD patientsMajor bleedingOAC useCardiovascular deathCKD stageHigher CHA
2008
Prediction of Cardiovascular Death using a Novel Heart Rate Recovery Parameter
HADLEY DM, DEWEY FE, FREEMAN JV, MYERS JN, FROELICHER VF. Prediction of Cardiovascular Death using a Novel Heart Rate Recovery Parameter. Medicine & Science In Sports & Exercise 2008, 40: 1072-1079. PMID: 18460999, DOI: 10.1249/mss.0b013e318167665a.Peer-Reviewed Original ResearchConceptsDuke treadmill scoreHeart rate recoveryHR increaseCV mortalityVagal toneCardiovascular causesCardiovascular deathPeak exerciseLowest tertileTreadmill scoreCox analysisClinical parametersMaximal exerciseSympathetic influencesExercise indexRate recoveryVagal influencePrognostic measurementMortalityPatientsRecovery variablesNormal scoresScoresExerciseRecovery parameters
2007
Novel predictor of prognosis from exercise stress testing: Heart rate variability response to the exercise treadmill test
Dewey FE, Freeman JV, Engel G, Oviedo R, Abrol N, Ahmed N, Myers J, Froelicher VF. Novel predictor of prognosis from exercise stress testing: Heart rate variability response to the exercise treadmill test. American Heart Journal 2007, 153: 281-288. PMID: 17239690, DOI: 10.1016/j.ahj.2006.11.001.Peer-Reviewed Original ResearchConceptsHeart rate variabilitySquare successive differenceCardiovascular mortalityPrognostic powerHF powerExercise treadmill testingRoot mean square successive differenceFrequency-domain HRV analysisExercise stress testingExercise treadmill testMortality end pointsSuccessive differencesStandard exercise testingHeart rate variability responsesMinutes of recoveryStrongest predictorLow-frequency powerMean square successive differenceHigh-frequency powerR interval dataCardiovascular deathCause mortalityPeak exerciseClinical factorsExercise testing
2006
P3-32 Integrated exercise induced temporal and spectral heart rate variability is a powerful prognostic marker for cardiovascular death
Hadley D, Freeman J, Dewey F, Engel G, Froelicher V. P3-32 Integrated exercise induced temporal and spectral heart rate variability is a powerful prognostic marker for cardiovascular death. Heart Rhythm 2006, 3: s188. DOI: 10.1016/j.hrthm.2006.02.564.Peer-Reviewed Original Research